Giancarlo Castaman

Medical Director Hematologist
Department of Oncology Careggi University Hospital, Florence, Italy
Florence, Toscana, Italy

Presentation(s):

• PB0238 - Clinical and patient-centered outcomes among Italian people with severe haemophilia A receiving prophylaxis: real-world findings from ‘Cost of Haemophilia: a Socio-economic Survey’ (CHESS) data base

  Sunday, June 23, 2024
  13:45 – 14:45 ICT

• PB0225 - High Bleed Control with a Single 225 µg/kg Eptacog Beta Dose in Adult and Adolescent Hemophilia A or B Persons with Inhibitors

  Sunday, June 23, 2024
  13:45 – 14:45 ICT

• PB0261 - Investigating effectiveness and safety of extended dosing regimens of damoctocog alfa pegol in the real-world HEM-POWR study

  Sunday, June 23, 2024
  13:45 – 14:45 ICT

• PB0231 - Treatment satisfaction and joint health outcomes within a real-world haemophilia B population: the Adelphi Disease Specific Programme™ survey

  Sunday, June 23, 2024
  13:45 – 14:45 ICT

• PB0503 - Clinical outcomes of people with hemophilia B treated with N9-GP in real-world settings: the Adelphi Disease Specific Programme™ hemophilia study

  Monday, June 24, 2024
  13:45 – 14:45 ICT

• OC 40.5 - Management of breakthrough bleeding episodes in the phase 3 concizumab studies

  Monday, June 24, 2024
  15:45 – 16:00 ICT

• OC 61.2 - Determinants of successful immune tolerance induction in people with severe hemophilia A

  Tuesday, June 25, 2024
  15:00 – 15:15 ICT

• OC 71.2 - Intracranial hemorrhage before the initiation of prophylaxis in early age in hemophilia A – data from the PedNet registry

  Wednesday, June 26, 2024
  10:30 – 10:45 ICT